GRP78-targeted nanotherapy against castrate-resistant prostate cancer cells expressing membrane GRP78. (Q39254849)

10 September 2017

title

GRP78-targeted nanotherapy against castrate-resistant prostate cancer cells expressing membrane GRP78. (English)

1 reference

10 September 2017

1 reference

Florence Delie

1

1 reference

10 September 2017

Patrick Petignat

series ordinal

2

1 reference

10 September 2017

Marie Cohen

series ordinal

3

1 reference

10 September 2017

publication date

23 October 2012

1 reference

10 September 2017

1 reference

10 September 2017

volume

8

1 reference

10 September 2017

issue

4

1 reference

10 September 2017

page(s)

225-230

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-012-0234-9

10 September 2017

exact match

0 references

cites work

GRP78 induction in cancer: therapeutic and prognostic implications.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Overexpression of glucose-regulated protein 78 in colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Phage display derived human monoclonal antibodies isolated by binding to the surface of live primary breast cancer cells recognize GRP78.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Identification of proteins associating with glycosylphosphatidylinositol- anchored T-cadherin on the surface of vascular endothelial cells: role for Grp78/BiP in T-cadherin-dependent cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

GRP78 and Cripto form a complex at the cell surface and collaborate to inhibit transforming growth factor beta signaling and enhance cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Ligation of cancer cell surface GRP78 with antibodies directed against its COOH-terminal domain up-regulates p53 activity and promotes apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Ligation of cell surface GRP78 with antibody directed against the COOH-terminal domain of GRP78 suppresses Ras/MAPK and PI 3-kinase/AKT signaling while promoting caspase activation in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

HPMA copolymer-aminohexylgeldanamycin conjugates targeting cell surface expressed GRP78 in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Surface modification of poly(lactic acid) nanoparticles by covalent attachment of thiol groups by means of three methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Mechanistic studies of a peptidic GRP78 ligand for cancer cell-specific drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

GRP78 Protein Expression in Ovarian Cancer Patients and Perspectives for a Drug-Targeting Approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Purified autoantibodies against glucose-regulated protein 78 (GRP78) promote apoptosis and decrease invasiveness of ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Active-targeted nanotherapy strategies for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

The formulation of aptamer-coated paclitaxel-polylactide nanoconjugates and their targeting to cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Targeting gene therapy for prostate cancer cells by liposomes complexed with anti-prostate-specific membrane antigen monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Fingerprinting the circulating repertoire of antibodies from cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Glucose regulated proteins in cancer progression, drug resistance and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0234-9

Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions

21 January 2018

1 reference

12 December 2020

Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands

1 reference

12 December 2020

Development of Secreted Protein and Acidic and Rich in Cysteine (SPARC) Targeted Nanoparticles for the Prognostic Molecular Imaging of Metastatic Prostate Cancer

1 reference

12 December 2020

Protein expression profiles in human breast ductal carcinoma and histologically normal tissue

1 reference

12 December 2020

Induction of M(r) 78,000 glucose-regulated stress protein in poly(adenosine diphosphate-ribose) polymerase- and nicotinamide adenine dinucleotide-deficient V79 cell lines and its relation to resistance to the topoisomerase II inhibitor etoposide.

1 reference

12 December 2020

1 reference

12 December 2020

10.1007/S11523-012-0234-9

Identifiers

DOI

1 reference

10 September 2017

1 reference